Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.00 Consensus Price Target from Analysts

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $8.00.

Several equities analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Cognition Therapeutics in a research report on Wednesday, November 27th. Chardan Capital reiterated a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a research note on Friday, November 15th. Finally, B. Riley restated a “neutral” rating and set a $1.00 target price (down from $5.00) on shares of Cognition Therapeutics in a research report on Tuesday, August 6th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CM Management LLC grew its position in shares of Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after acquiring an additional 25,000 shares during the last quarter. Sigma Planning Corp raised its stake in Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its position in shares of Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the period. Virtu Financial LLC acquired a new position in shares of Cognition Therapeutics in the 3rd quarter valued at $27,000. Finally, Bangor Savings Bank increased its position in Cognition Therapeutics by 41.6% during the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock worth $56,000 after purchasing an additional 10,000 shares in the last quarter. 43.35% of the stock is owned by institutional investors and hedge funds.

Cognition Therapeutics Price Performance

Shares of CGTX opened at $0.40 on Friday. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The business’s 50 day simple moving average is $0.47 and its 200-day simple moving average is $1.09. The stock has a market capitalization of $16.70 million, a price-to-earnings ratio of -0.41 and a beta of 1.34.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.